Cargando…
Synovial tissue volume: a treatment target in knee osteoarthritis (OA)
BACKGROUND: Synovitis occurring frequently in osteoarthritis (OA) may be a targeted outcome. There are no data examining whether synovitis changes following intra-articular intervention. METHODS: Persons aged 40 years and older with painful knee OA participated in an open label trial of intra-articu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717397/ https://www.ncbi.nlm.nih.gov/pubmed/26116548 http://dx.doi.org/10.1136/annrheumdis-2014-206927 |
_version_ | 1782410648598085632 |
---|---|
author | O'Neill, Terence W Parkes, Matthew J Maricar, Nasimah Marjanovic, Elizabeth J Hodgson, Richard Gait, Andrew D Cootes, Timothy F Hutchinson, Charles E Felson, David T |
author_facet | O'Neill, Terence W Parkes, Matthew J Maricar, Nasimah Marjanovic, Elizabeth J Hodgson, Richard Gait, Andrew D Cootes, Timothy F Hutchinson, Charles E Felson, David T |
author_sort | O'Neill, Terence W |
collection | PubMed |
description | BACKGROUND: Synovitis occurring frequently in osteoarthritis (OA) may be a targeted outcome. There are no data examining whether synovitis changes following intra-articular intervention. METHODS: Persons aged 40 years and older with painful knee OA participated in an open label trial of intra-articular steroid therapy. At all time points they completed the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire. They had a contrast-enhanced (CE) MRI immediately prior to an intra-articular steroid injection with a repeat scan within 20 days. Response status was assessed using the Osteoarthritis Research Society International (OARSI) response criteria. OARSI responders were followed until their pain relapsed either within 20% of baseline or 6 months, shortly after which a third MRI was performed. Synovial tissue volume (STV) was measured on postcontrast knee images. We looked at changes in the STV and in pain, and their association. RESULTS: 120 subjects with preinjection and postinjection CE MRI were followed. Their mean age was 62.3 years (SD=10.3) and 62 (52%) were women. The median time between injection and follow-up scan was 8 days (IQR 7–14 days). 85/120 (71%) were OARSI responders. Pain decreased (mean change in KOOS=+23.9; 95% CI 20.1 to 27.8, p<0.001) following steroid injection, as did mean STV (mean change=−1071 mm(3); 95% CI −1839 mm(3) to −303 mm(3), p=0.01). Of the 80 who returned for a third MRI, pain relapsed in 57, and in the 48 of those with MRI data, STV increased between follow-up and final visit (+1220 mm(3); 95% CI 25 mm(3) to 2414 mm(3), p=0.05). 23 were persistent responders at 6 months and, in these, STV did not increase (mean change=−202 mm(3); 95% CI −2008 mm(3) to 1604 mm(3), p=0.83). Controlling for variation over time, there was a significant association between synovitis volume and KOOS pain (b coefficient—change in KOOS pain score per 1000 mm(3) change in STV=−1.13; 95% CI −1.87 to −0.39, p=0.003), although STV accounted for only a small proportion of the variance in change in pain. CONCLUSIONS: Synovial tissue volume in knee OA shrinks following steroid therapy, and rebounds in those whose pain relapses. It can be considered a treatment target in symptomatic knee OA. TRIAL REGISTRATION NUMBER: ISRCTN07329370. |
format | Online Article Text |
id | pubmed-4717397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-47173972016-01-28 Synovial tissue volume: a treatment target in knee osteoarthritis (OA) O'Neill, Terence W Parkes, Matthew J Maricar, Nasimah Marjanovic, Elizabeth J Hodgson, Richard Gait, Andrew D Cootes, Timothy F Hutchinson, Charles E Felson, David T Ann Rheum Dis Clinical and Epidemiological Research BACKGROUND: Synovitis occurring frequently in osteoarthritis (OA) may be a targeted outcome. There are no data examining whether synovitis changes following intra-articular intervention. METHODS: Persons aged 40 years and older with painful knee OA participated in an open label trial of intra-articular steroid therapy. At all time points they completed the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire. They had a contrast-enhanced (CE) MRI immediately prior to an intra-articular steroid injection with a repeat scan within 20 days. Response status was assessed using the Osteoarthritis Research Society International (OARSI) response criteria. OARSI responders were followed until their pain relapsed either within 20% of baseline or 6 months, shortly after which a third MRI was performed. Synovial tissue volume (STV) was measured on postcontrast knee images. We looked at changes in the STV and in pain, and their association. RESULTS: 120 subjects with preinjection and postinjection CE MRI were followed. Their mean age was 62.3 years (SD=10.3) and 62 (52%) were women. The median time between injection and follow-up scan was 8 days (IQR 7–14 days). 85/120 (71%) were OARSI responders. Pain decreased (mean change in KOOS=+23.9; 95% CI 20.1 to 27.8, p<0.001) following steroid injection, as did mean STV (mean change=−1071 mm(3); 95% CI −1839 mm(3) to −303 mm(3), p=0.01). Of the 80 who returned for a third MRI, pain relapsed in 57, and in the 48 of those with MRI data, STV increased between follow-up and final visit (+1220 mm(3); 95% CI 25 mm(3) to 2414 mm(3), p=0.05). 23 were persistent responders at 6 months and, in these, STV did not increase (mean change=−202 mm(3); 95% CI −2008 mm(3) to 1604 mm(3), p=0.83). Controlling for variation over time, there was a significant association between synovitis volume and KOOS pain (b coefficient—change in KOOS pain score per 1000 mm(3) change in STV=−1.13; 95% CI −1.87 to −0.39, p=0.003), although STV accounted for only a small proportion of the variance in change in pain. CONCLUSIONS: Synovial tissue volume in knee OA shrinks following steroid therapy, and rebounds in those whose pain relapses. It can be considered a treatment target in symptomatic knee OA. TRIAL REGISTRATION NUMBER: ISRCTN07329370. BMJ Publishing Group 2016-01 2015-06-26 /pmc/articles/PMC4717397/ /pubmed/26116548 http://dx.doi.org/10.1136/annrheumdis-2014-206927 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Clinical and Epidemiological Research O'Neill, Terence W Parkes, Matthew J Maricar, Nasimah Marjanovic, Elizabeth J Hodgson, Richard Gait, Andrew D Cootes, Timothy F Hutchinson, Charles E Felson, David T Synovial tissue volume: a treatment target in knee osteoarthritis (OA) |
title | Synovial tissue volume: a treatment target in knee osteoarthritis (OA) |
title_full | Synovial tissue volume: a treatment target in knee osteoarthritis (OA) |
title_fullStr | Synovial tissue volume: a treatment target in knee osteoarthritis (OA) |
title_full_unstemmed | Synovial tissue volume: a treatment target in knee osteoarthritis (OA) |
title_short | Synovial tissue volume: a treatment target in knee osteoarthritis (OA) |
title_sort | synovial tissue volume: a treatment target in knee osteoarthritis (oa) |
topic | Clinical and Epidemiological Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717397/ https://www.ncbi.nlm.nih.gov/pubmed/26116548 http://dx.doi.org/10.1136/annrheumdis-2014-206927 |
work_keys_str_mv | AT oneillterencew synovialtissuevolumeatreatmenttargetinkneeosteoarthritisoa AT parkesmatthewj synovialtissuevolumeatreatmenttargetinkneeosteoarthritisoa AT maricarnasimah synovialtissuevolumeatreatmenttargetinkneeosteoarthritisoa AT marjanovicelizabethj synovialtissuevolumeatreatmenttargetinkneeosteoarthritisoa AT hodgsonrichard synovialtissuevolumeatreatmenttargetinkneeosteoarthritisoa AT gaitandrewd synovialtissuevolumeatreatmenttargetinkneeosteoarthritisoa AT cootestimothyf synovialtissuevolumeatreatmenttargetinkneeosteoarthritisoa AT hutchinsoncharlese synovialtissuevolumeatreatmenttargetinkneeosteoarthritisoa AT felsondavidt synovialtissuevolumeatreatmenttargetinkneeosteoarthritisoa |